UA118656C2 - Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції - Google Patents

Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції

Info

Publication number
UA118656C2
UA118656C2 UAA201503523A UAA201503523A UA118656C2 UA 118656 C2 UA118656 C2 UA 118656C2 UA A201503523 A UAA201503523 A UA A201503523A UA A201503523 A UAA201503523 A UA A201503523A UA 118656 C2 UA118656 C2 UA 118656C2
Authority
UA
Ukraine
Prior art keywords
bremelanotide
treatment
sexual dysfunction
female sexual
application
Prior art date
Application number
UAA201503523A
Other languages
English (en)
Ukrainian (uk)
Inventor
Карл Спана
Роберт Джордан
Джеффрі Д. Еделсон
Original Assignee
Пелетін Текнолоджіз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA118656(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Пелетін Текнолоджіз, Інк. filed Critical Пелетін Текнолоджіз, Інк.
Publication of UA118656C2 publication Critical patent/UA118656C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
UAA201503523A 2012-11-05 2013-11-05 Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції UA118656C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261722511P 2012-11-05 2012-11-05
US201361770535P 2013-02-28 2013-02-28
PCT/US2013/068386 WO2014071339A2 (en) 2012-11-05 2013-11-05 Uses of bremelanotide in therapy for female sexual dysfunction

Publications (1)

Publication Number Publication Date
UA118656C2 true UA118656C2 (uk) 2019-02-25

Family

ID=50628268

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201503523A UA118656C2 (uk) 2012-11-05 2013-11-05 Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції

Country Status (23)

Country Link
US (7) US9352013B2 (enExample)
EP (1) EP2916856B2 (enExample)
JP (1) JP6567971B2 (enExample)
KR (1) KR102253526B1 (enExample)
CN (2) CN104755094A (enExample)
AU (1) AU2013337341B2 (enExample)
BR (1) BR112015009936A8 (enExample)
DK (1) DK2916856T4 (enExample)
EA (1) EA032959B9 (enExample)
ES (1) ES2701444T5 (enExample)
FI (1) FI2916856T4 (enExample)
GE (2) GEP20196947B (enExample)
HK (1) HK1211227A1 (enExample)
IL (1) IL238276B (enExample)
MX (1) MX362610B (enExample)
MY (1) MY179755A (enExample)
NZ (1) NZ707246A (enExample)
PH (1) PH12015500915A1 (enExample)
PL (1) PL2916856T5 (enExample)
SG (1) SG11201502949QA (enExample)
UA (1) UA118656C2 (enExample)
WO (1) WO2014071339A2 (enExample)
ZA (1) ZA201503128B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension
CN119074641A (zh) * 2024-09-02 2024-12-06 万邦德制药集团有限公司 一种含布雷默浪丹药物组合物、制剂及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
JP4943622B2 (ja) * 2000-05-31 2012-05-30 ノヴォ ノルディスク アー／エス 使い捨て可能で両端が尖った注射針並びにこの使い捨て可能で両端が尖った注射針を有するインシュリン注射システム
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
WO2006063172A2 (en) * 2004-12-09 2006-06-15 West Pharmaceutical Services, Inc. Breech loaded fixed needle syringe and automatic injection device having the same
WO2009151714A2 (en) * 2008-03-24 2009-12-17 Palatin Technologies, Inc. Therapeutic for treatment of circulatory shock, ischemia, inflammatory disease and related conditions
JP5628796B2 (ja) * 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
US9314509B2 (en) * 2009-11-16 2016-04-19 Ipsen Pharma S.A.S. Pharmaceutical compositions of melanocortin receptor ligands
NZ702172A (en) * 2010-04-21 2016-03-31 Abbvie Biotechnology Ltd Wearable automatic injection device for controlled delivery of therapeutic agents

Also Published As

Publication number Publication date
PL2916856T3 (pl) 2019-02-28
ES2701444T5 (es) 2024-05-21
ES2701444T3 (es) 2019-02-22
DK2916856T4 (da) 2024-01-22
US20140378392A1 (en) 2014-12-25
KR20150081345A (ko) 2015-07-13
EA032959B1 (ru) 2019-08-30
KR102253526B1 (ko) 2021-05-18
HK1211227A1 (en) 2016-05-20
EA032959B9 (ru) 2019-11-27
US20210060120A1 (en) 2021-03-04
US9700592B2 (en) 2017-07-11
CN117860866A (zh) 2024-04-12
BR112015009936A2 (pt) 2017-07-11
ZA201503128B (en) 2016-11-30
IL238276B (en) 2020-04-30
PL2916856T5 (pl) 2024-01-29
US10286034B2 (en) 2019-05-14
EP2916856A4 (en) 2016-06-22
MY179755A (en) 2020-11-12
PH12015500915B1 (en) 2015-06-29
AU2013337341B2 (en) 2018-02-22
PH12015500915A1 (en) 2015-06-29
US9352013B2 (en) 2016-05-31
WO2014071339A3 (en) 2014-06-12
CA2890081A1 (en) 2014-05-08
JP2016503406A (ja) 2016-02-04
WO2014071339A2 (en) 2014-05-08
EP2916856A2 (en) 2015-09-16
SG11201502949QA (en) 2015-06-29
US20220362328A1 (en) 2022-11-17
FI2916856T4 (fi) 2024-01-15
CN104755094A (zh) 2015-07-01
US20190216888A1 (en) 2019-07-18
MX362610B (es) 2019-01-28
US20240335502A1 (en) 2024-10-10
BR112015009936A8 (pt) 2019-09-17
DK2916856T3 (en) 2019-01-14
GEP20196947B (en) 2019-02-11
EA201590760A1 (ru) 2015-10-30
GEAP201813826A (en) 2018-10-25
EP2916856B1 (en) 2018-09-19
AU2013337341A1 (en) 2015-05-07
MX2015005486A (es) 2015-11-13
JP6567971B2 (ja) 2019-08-28
NZ707246A (en) 2019-03-29
US20150231196A1 (en) 2015-08-20
US20180085425A1 (en) 2018-03-29
IL238276A0 (en) 2015-06-30
EP2916856B2 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
MX2021002321A (es) Nuevos metodos.
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MY189466A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
NZ714963A (en) Compositions and methods for treating anemia
NZ732507A (en) Improved compositions for treating muscular dystrophy
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
PH12014500386A1 (en) Combination treatment for hepatitis c
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
UA117581C2 (uk) Протипухлинний лікарський засіб, який включає низькодозований гідрохлориду іринотекану гідрат
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
EA201690974A1 (ru) Гидроморфон и налоксон для лечения боли и индуцированного опиоидами синдрома дисфункции кишечника
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12017500617A1 (en) Dosage regimen for pegylated interferon
UA118656C2 (uk) Застосування бремеланотиду у лікуванні жіночої сексуальної дисфункції
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
ZA202102913B (en) Dosage regime